Zeria Plans 2009 Test Of Compound For Easing Cancer Pain
This article was originally published in PharmAsia News
Executive Summary
Japan's Zeria Pharmaceutical says it expects to begin Phase II trials in Europe next year to test its pancreatic cancer compound, Z-360. The drug was developed to treat stomach ulcers, but Zeria redeveloped it to treat gastrointestinal cancers. Z-360 failed in previous trials to shrink tumors, but researchers noted it helped to ease patient pain. In next year's trials, Zeria plans to test the gastrin CCK2 receptor antagonist in combination with Eli Lilly's Gemzar (gemcitabine). (Click here for more - a subscription may be required
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.